

**Supplementary Table S11. Renal cancer patient characteristics, median survival, and Multivariate Cox Regression Modeling.**

Patient Characteristics: Kidney		LOR	ALP	No Benzo	Overall	P-value
	N	73 (12.4)	38 (6.5)	477 (81.1)	588 (100%)	
Sex	Female	25 (34.2%)	21 (55.3%)	185 (38.8%)	231 (39.3%)	0.087
	Male	48 (65.8%)	17 (44.7%)	292 (61.2%)	357 (60.7%)	
Grade (Clinical)	I		3 (7.9%)	23 (4.9%)	26 (4.5%)	0.288
	II	18 (24.7%)	11 (28.9%)	131 (28.0%)	160 (27.6%)	
	III	24 (32.9%)	13 (34.2%)	135 (28.8%)	172 (29.7%)	
	IV	6 (8.2%)	2 (5.3%)	59 (12.6%)	67 (11.6%)	
	Not Reported	25 (34.2%)	9 (23.7%)	120 (25.6%)	154 (26.6%)	
Grade (Pathological)	I		3 (7.9%)	23 (4.9%)	26 (4.5%)	0.435
	II	18 (24.7%)	10 (26.3%)	129 (27.5%)	157 (27.1%)	
	III	23 (31.5%)	13 (34.2%)	136 (29.0%)	172 (29.7%)	
	IV	8 (11.0%)	2 (5.3%)	60 (12.8%)	70 (12.1%)	
	Not Reported	24 (32.9%)	10 (26.3%)	121 (25.8%)	155 (26.7%)	
Stage (Clinical)	I	13 (17.8%)	9 (24.3%)	133 (27.9%)	155 (26.4%)	0.412
	II	4 (5.5%)	1 (2.7%)	44 (9.2%)	49 (8.3%)	
	III	4 (5.5%)	1 (2.7%)	24 (5.0%)	29 (4.9%)	
	IV	16 (21.9%)	7 (18.9%)	78 (16.4%)	101 (17.2%)	
	Not Reported	36 (49.3%)	19 (51.4%)	198 (41.5%)	253 (43.1%)	
Stage (Pathological)	I	10 (13.7%)	7 (18.9%)	106 (22.2%)	123 (21.0%)	0.482
	II	3 (4.1%)	2 (5.4%)	32 (6.7%)	37 (6.3%)	
	III	5 (6.8%)	2 (5.4%)	47 (9.9%)	54 (9.2%)	
	IV	9 (12.3%)	5 (13.5%)	39 (8.2%)	53 (9.0%)	
	Not Reported	46 (63.0%)	21 (56.8%)	253 (53.0%)	320 (54.5%)	
Overall Survival Indicator	Alive	26 (35.6%)	16 (42.1%)	229 (48.0%)	271 (46.1%)	0.124
	Dead	47 (64.4%)	22 (57.9%)	248 (52.0%)	317 (53.9%)	
Progression-Free Survival Indicator	No Progression	20 (27.4%)	13 (34.2%)	205 (43.0%)	238 (40.5%)	0.030
	Progression	53 (72.6%)	25 (65.8%)	272 (57.0%)	350 (59.5%)	

Overall Survival (OS)	Median Surv. (95% CI)	Sample: Kidney	Log Rank P-value
Total	82.4 (65.6, 96.0)	E=317 C=271 T=588	p= 0.272
ALP	66.9 (24.0, 120.6)	E=22 C=16 T=38	
LOR	66.9 (48.3, 96.0)	E=47 C=26 T=73	
No Benzo	86.8 (66.2, 105.9)	E=248 C=229 T=477	

Progression-Free Survival (PFS)	Median Surv. (95% CI)	Sample: Kidney	Log Rank P-value
Total	49.1 (38.3, 66.8)	E=350 C=238 T=588	p= 0.051
ALP	35.6 (13.9, 95.7)	E=25 C=13 T=38	
LOR	36.8 (26.1, 53.8)	E=53 C=20 T=73	
No Benzo	59.8 (39.1, 79.2)	E=272 C=205 T=477	

Overall Survival (OS)		
Predictors: Cohort, Sex, Clinical Grade, and Clinical Stage		
Cohort	HR (95% CI)	P-value
No Benzo	Ref.	0.6198
ALP	1.153 (0.741 – 1.795)	0.5268
LOR	0.898 (0.651 – 1.240)	0.5132
Progression-Free Survival (PFS)		
No Benzo	Ref.	0.7907
ALP	1.152 (0.760 – 1.747)	0.5058
LOR	1.039 (0.768 – 1.407)	0.8034

**E= event, C= censored, T= Total**